Leta i den här bloggen

söndag 11 juni 2023

Vertailen taulukoita . Viikon 20 prevalenssi tiedot lisätty edellisen (Viikot 14-18) taulukon tietoihin.

Download 8.6. 2023 sisältää paljon selventäviä käyriä ja tekstejä: Kts WHO linkistä.
Figure 7. Top three SARS-CoV-2 variants (including non-VOIs/VUMs) by WHO region, epidemiological week 16 to week 20 of 2023

Figure 8. The number and percentage of SARS-CoV-2 sequences, from 1 January to 21 May 2023

Figure 8. Panel A shows the number, and Panel B the percentage, of all circulating variants since January 2023. Omicron sister-lineages and additional Omicron VOC descendent lineages under further monitoring are shown. BA.1*, BA.2*, BA.3*, BA.4* and BA.5* (* indicates inclusion of descendent lineages) include all BA.1, BA.2, BA.3, BA.4 and BA.5 pooled descendent lineages, except currently circulating variants shown individually. The
Unassigned category includes lineages pending for a PANGO lineage name, whereas the Other category includes lineages that are assigned but not listed in the legend. Source: SARS- CoV-2 sequence data and metadata from GISAID, from 1 January 2023 to 21 May 2023.
)Among the VUMs, XBB, XBB.1.9.1, XBB.1.9.2, and XBB.2.3 have shown increasing trends

Edellinen  taulukko  kuuakuden takaa: + viikko 20 lisättynä.  uudet  sekvenssimäärät punaisella.
Table 2. Weekly prevalence of SARS-CoV-2 VOIs and VUMs, week 14 to week 18 of 2023
+ w.20
Lineage
  Countries§   Sequences§    2023-14, 2023-15, 2023-16, 2023-17, 2023-18, 2023-20
XBB.1.5* (VOI)
116 c.  240,457  seq   50.44      49.44     46.41     45.65          41.57    30.28%.
XBB.1.16* (VOI)
65 c.   16,368   seq     6.92       8.55     10.01     10.73          13.17     16,81%.
BA.2.75*
          123  c.111,956  seq      3.28      2.84       2.42        1.00            1.17         1,19%
CH.1.1*
               92 c.  46,871  seq      3.85       3.77      3.15        2.86            2.26          1,96%
BQ.1*
               150 c. 411,412  seq      3.73       2.83      2.06        1.42            0.75         0.34%
XBB*
                 127 c.  64,360 seq      6.28       6.76       7.21       9.02          10.80          5,27%
XBB.1.9.1*
         90  c.  31,583  seq   10.57      11.93      13.34    14.79          15.65       18,19%
XBB.1.9.2*         64
  c.    8,426  seq     2.65        3.25        4.14      4.77            5.15          6,63%
XBB.2.3*
             55  c.   6,359  seq     1.95        2.18        2.52      2.88           3.59           7,09%
Unassigned
       103 c.  149,639 seq     2.13      1.26        0.93      0.03            -                   1,4%
Other+
            207c.  6.724,206 seq    6.14      6.40        7.28      8.16             7.94           10,47%
Includes descendant lineages, except those individually specified elsewhere in the table. For example, XBB* does not include XBB.1.5, XBB.1.9.1,XBB.1.9.2, XBB.1.16, and XBB.2.3.
+ Others are other circulating lineages excluding the VOI, VUMs, BA.1*, BA.2*, BA.3*, BA.4*, BA.5*.

§ Countries and sequences are since the emergence of the variants

 
SARS-CoV-2 variants of interest
and variants under monitoring
Geographic spread and prevalence

Globally, from 8 May to 4 June 2023 (28 days), 17 523 SARS-CoV-2 sequences were shared through GISAID. WHO is currently tracking two variants of interest (VOIs), XBB.1.5 and XBB.1.16, along with seven variants under monitoring
(VUMs) and their descendent lineages. The VUMs are BA.2.75, CH.1.1, BQ.1, XBB, XBB.1.9.1, XBB.1.9.2 and XBB.2.3.


There has been an increase in the number of countries reporting the two VOIs.

 Between 10 April and 7 May 2023 (28 days), 61 countries reported XBB.1.5 sequences, a cumulative total of 116 countries as of 21 May 2023 (Figure 6A,

 
Table 2). During the same 28-day period, 51 countries reported XBB.1.16 sequences, bringing the cumulative total to 65 countries (Figure 6B, Table 2).

 While XBB.1.5 remains dominant globally, its prevalence has been declining steadily. In epidemiological week 20 (15 to 21 May 2023), XBB.1.5 accounted for 30.3% of sequences, a decline from 46.2% in week 16 (17 to 23 April 2023).

  Globally, XBB.1.16 continues to rise in prevalence, accounting for 16.8% of
sequences in week 20 compared to 10.2% in week 16.

 

 

 

( Kuukausi sitten : Asetan Viikon 20 tähän yläpuolelle  mukaan. ja korjaan uudet arvot  viikolta 20 punaisella : 


Table 2. Weekly prevalence of SARS-CoV-2 VOIs and VUMs, week 14 to week 18 of 2023

Lineage
  Countries§   Sequences§    2023-14, 2023-15, 2023-16, 2023-17, 2023-18
XBB.1.5* (VOI)
113 c.  227033 seq   50.44      49.44     46.41     45.65          41.57
XBB.1.16* (VOI)
58 c.   11857  seq     6.92       8.55     10.01     10.73          13.17

BA.2.75*
          123  c.111031  seq      3.28      2.84       2.42        1.00            1.17
CH.1.1*
               91 c.  45949  seq      3.85       3.77      3.15        2.86            2.26
BQ.1*
               149 c. 410340  seq      3.73       2.83      2.06        1.42            0.75
XBB*
                 127 c.   67073 seq      6.28       6.76       7.21       9.02          10.80
XBB.1.9.1*
         84  c.  26149  seq   10.57      11.93      13.34    14.79          15.65
XBB.1.9.2*         
58  c.    6805  seq     2.65        3.25        4.14      4.77            5.15
XBB.2.3*
             52  c.    3657  seq     1.95        2.18        2.52      2.88           3.59

Unassigned
       103 c.  149154 seq     2.13      1.26        0.93      0.03            -
Other+
               207c.  6710043 seq    6.14      6.40        7.28      8.16             7.94
* Includes descendant lineages, except those individually specified elsewhere in the table. For example, XBB* does not include XBB.1.5, XBB.1.9.1,
XBB.1.9.2, XBB.1.16, and XBB.2.3.

+ Others are other circulating lineages excluding the VOI, VUMs, BA.1*, BA.2*, BA.3*, BA.4*, BA.5*.

§ Countries and sequences are since the emergence of the variants

Additional resources

Tracking SARS-CoV-2 Variants

WHO statement on updated tracking system on SARS-CoV-2 variants of concern and variants of interest

WHO XBB.1.16 Initial Risk Assessment, 17 April 2023

WHO XBB.1.5 rapid risk assessment, 24 February 2023

Inga kommentarer:

Skicka en kommentar